Nicholas Augustinos Sells 1,550 Shares of DexCom (NASDAQ:DXCM) Stock

DexCom, Inc. (NASDAQ:DXCM) Director Nicholas Augustinos sold 1,550 shares of the stock in a transaction on Monday, September 14th. The shares were sold at an average price of $84.02, for a total value of $130,231.00. Following the sale, the director owned 35,832 shares in the company, valued at approximately $3,010,604.64. This represents a 4.15% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Nicholas Augustinos also recently made the following trade(s):

• On Tuesday, September 15th, Nicholas Augustinos sold 6,539 shares of DexCom stock. The stock was sold at an average price of $84.04, for a total value of $549,537.56.

DexCom Trading Up 0.7%

Shares of NASDAQ:DXCM opened at $87.93 on Friday. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.73 and a quick ratio of 1.43. DexCom, Inc. has a 1 year low of $54.11 and a 1 year high of $92.59. The company has a market cap of $33.18 billion, a P/E ratio of 34.76, a PEG ratio of 1.46 and a beta of 1.42. The stock’s fifty day moving average price is $83.82 and its 200-day moving average price is $73.17.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, July 30th. The medical device company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.61 by $0.09. The company had revenue of $1.31 billion during the quarter, compared to the consensus estimate of $1.29 billion. DexCom had a return on equity of 35.94% and a net margin of 20.12%.DexCom’s revenue for the quarter was up 13.1% on a year-over-year basis. During the same period last year, the company earned $0.48 EPS. Sell-side analysts expect that DexCom, Inc. will post 2.64 earnings per share for the current year.

Institutional Trading of DexCom

Large investors have recently added to or reduced their stakes in the business. Plato Investment Management Ltd purchased a new position in DexCom during the second quarter valued at approximately $782,000. Aurora Investment Counsel purchased a new stake in shares of DexCom in the second quarter worth $2,340,000. E Fund Management Co. Ltd. purchased a new stake in shares of DexCom in the second quarter worth $1,273,000. Silvant Capital Management LLC bought a new stake in shares of DexCom during the 2nd quarter valued at $5,359,000. Finally, Performance Wealth Partners LLC bought a new stake in shares of DexCom during the 2nd quarter valued at $1,740,000. 97.75% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

DXCM has been the topic of a number of research analyst reports. Weiss Ratings upgraded shares of DexCom from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 11th. Wells Fargo & Company boosted their target price on shares of DexCom from $85.00 to $90.00 and gave the company an “overweight” rating in a research note on Friday, July 31st. Robert W. Baird set a $105.00 price target on DexCom in a report on Friday, July 31st. Truist Financial set a $93.00 price target on DexCom and gave the stock a “buy” rating in a research note on Friday, July 31st. Finally, TD Cowen reaffirmed a “buy” rating on shares of DexCom in a report on Friday, July 31st. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $88.71.

DexCom Company Profile

DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems that measure glucose levels in real time. Its technology is designed to help people with diabetes monitor glucose trends and make more informed treatment and lifestyle decisions without relying solely on traditional fingerstick testing.

The company’s products include the Dexcom G7 and Dexcom G6 CGM systems, which use a small wearable sensor, transmitter or integrated sensor, and mobile applications to display glucose data.